| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/18/2000 | US6090823 Administering n,n'-propylenedinicotinamide |
| 07/18/2000 | US6090822 Treatment of cytokine growth factor caused disorders |
| 07/18/2000 | US6090820 Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones |
| 07/18/2000 | US6090819 Use of NK-1 receptor antagonists for treating mania |
| 07/18/2000 | US6090818 Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them |
| 07/18/2000 | US6090817 Respiratory system disorders; phosphodiesterse inhibitor |
| 07/18/2000 | US6090816 Antiasthma agents |
| 07/18/2000 | US6090814 Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization |
| 07/18/2000 | US6090813 Use of oxido-squalene cyclase inhibitors to lower blood cholesterol |
| 07/18/2000 | US6090812 Therapy for psychological, central nervous system disorders |
| 07/18/2000 | US6090811 Analgesic |
| 07/18/2000 | US6090810 Side effect reduction |
| 07/18/2000 | US6090809 1-(4-arylpiperazin-1-yl)-ω-[n-(α..omega.-dicarboximido)]-alkanes useful as uro-selective α1 -adrenoceptor blockers |
| 07/18/2000 | US6090808 Dimeric piperidine, tetrahydropyridine and piperazine derivatives |
| 07/18/2000 | US6090807 Use of heterocyclic compounds |
| 07/18/2000 | US6090804 Psychological disorders; schizophrenia therapy |
| 07/18/2000 | US6090801 Pharmaceutical compositions containing ceftriaxone and penems |
| 07/18/2000 | US6090799 Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1 |
| 07/18/2000 | US6090798 Treatment of GLC1A glaucoma with glucocorticoid antagonists |
| 07/18/2000 | US6090796 Anticancer, antitumor agent; viricide |
| 07/18/2000 | US6090794 Inhibition of neurofibrosarcoma growth and angiogenesis |
| 07/18/2000 | US6090792 Maltose-trehalose converting enzyme, and preparation and uses thereof |
| 07/18/2000 | US6090791 Method for inducing mucosal immunity |
| 07/18/2000 | US6090789 Synthesis of the breast tumor-associated antigen defined by monoclonal antibody MBr1 and uses thereof |
| 07/18/2000 | US6090788 Irradiating the area of skin or nail with a light beam having at least one wavelength absorbable by the pathogen to destruct the fungal pathogen |
| 07/18/2000 | US6090779 Use of hemoglobin to treat septic shock |
| 07/18/2000 | US6090778 Neurturin and related growth factors |
| 07/18/2000 | US6090618 DNA constructs and viral vectors comprising a smooth muscle promoter |
| 07/18/2000 | US6090610 Macrolide compound 0406 |
| 07/18/2000 | US6090602 Inhibiting hybridization of a reverse-transcribing dna strand with an rna template by delivering 1'-adenyl-, 1'-cytodinyl-, 1'-guanyl-, 1'-thymidyl-, or 1'-uridinyl-l-rhamnose; analog is phorphorylated and incorporated into synthesized dna |
| 07/18/2000 | US6090583 Expression system in compatible host cell of a polynucleotide which produces a metalloprotease; diagnosis and treatment of asthma, disorders of leukotriene metabolism; anticarcinogenic agents; antiinflammatory/antidiabetic/antiarthritic agents |
| 07/18/2000 | US6090579 Human SDR2 cDNA clone |
| 07/18/2000 | US6090565 Measuring level of at least one glucosylceramide in said test cell and comparing to level in non-drug resistant cell; higher level indicates resistance |
| 07/18/2000 | US6090544 Screening for compounds capable of activating osteogenic protein-1-responsive transcription activating element by transforming cell with dna of element linked to reporter gene, exposing cell to compound, determining gene expression |
| 07/18/2000 | US6090542 Inhibiting the activity of nf-kb, a transcription factor, by treating the cells with a substance which specifically inhibits the proteolytic degradation of ikb-alpha |
| 07/18/2000 | US6090414 Method and composition to reduce cancer incidence |
| 07/18/2000 | US6090411 Monolithic tablet for controlled drug release |
| 07/18/2000 | US6090410 Dry mix formulation for bisphosphonic acids |
| 07/18/2000 | US6090409 Therapeutic uses of finasteride |
| 07/18/2000 | US6090407 Administering anticancer drug to respiratory system |
| 07/18/2000 | US6090405 Multilayer; backing layer and pressure sensitive adhesive |
| 07/18/2000 | US6090404 Sustained release patch |
| 07/18/2000 | US6090400 Pharmaceutical preparation and method for treatment of diabetes |
| 07/18/2000 | US6090395 Skin antiseptics; alcohol and chlorhexidine digluconate, with thickener |
| 07/18/2000 | US6090394 For humans, animals |
| 07/18/2000 | US6090382 Human antibodies that bind human TNFα |
| 07/18/2000 | US6090378 Cells which are allogeneic or xenogeneic for mammal, comprise a gene encoding interleukin-2, and a retrovirus which infects dividing cells of mammal and comprises a gene encoding thymidine kinase; antitumor agent |
| 07/18/2000 | US6090374 Cosmetic and pharmaceutical preparations comprising photostable UV filters |
| 07/18/2000 | US6090368 Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine |
| 07/18/2000 | US6090112 Spine distraction implant and method |
| 07/18/2000 | CA2295790A1 Controlled release tramadol preparations having a storage-stable table release profile and process for the production thereof |
| 07/18/2000 | CA2295471A1 Opioid analgesics with controlled active substance release |
| 07/18/2000 | CA2295470A1 Process for the preparation of pellets with a content of up to 90 wt.% of a pharmaceutical active ingredient |
| 07/18/2000 | CA2295469A1 Analgesic with controlled active substance release |
| 07/18/2000 | CA2259730A1 Sustained release tablets containing bupropion hydrochloride |
| 07/18/2000 | CA2183954C Treatment of obsessive-compulsive disorders with 5-ht2 antagonists |
| 07/18/2000 | CA2178528C Therapeutics containing 5alpha - reductase inhibitors |
| 07/18/2000 | CA2148651C Halogenated antifungal and antibacterial compounds used for reducing hair loss |
| 07/18/2000 | CA2132933C Soft gelatin capsule manufacture |
| 07/18/2000 | CA2129051C Absorbable composite materials for use in the treatment of periodontal disease |
| 07/18/2000 | CA2117610C Indole derivatives as steroid 5 alpha-reductase inhibitors |
| 07/18/2000 | CA2113656C Isolation and structure of spongistatin 1 |
| 07/18/2000 | CA2111527C Phosphonooxymethyl ethers of taxane derivatives |
| 07/18/2000 | CA2093927C Ligand-mediated immunofunctional hormone binding protein assay method |
| 07/18/2000 | CA2045142C Process for the preparation and purification of a mixture of glycosphingolipids, free from contamination by non-conventional viruses |
| 07/18/2000 | CA2022183C Arylpyrazole derivatives as anti-platelet agents |
| 07/18/2000 | CA2017376C Diarylstyrylquinoline diacids |
| 07/18/2000 | CA2008616C Aryl- or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions |
| 07/18/2000 | CA2008183C Liquid pharmaceutical composition for piperidinoalkanol derivatives |
| 07/18/2000 | CA2006716C Antibacterial antiplaque oral composition |
| 07/18/2000 | CA2004332C Inhibition of cell adhesion |
| 07/18/2000 | CA2003289C Use of trifluoromethylphenyl-tetrahydropyridines for the preparation of pharmaceutical compositions useful for the treatment of anxiety and anxio-depressive disorders |
| 07/13/2000 | WO2000040965A1 Fxr receptor-mediated modulation of cholesterol metabolism |
| 07/13/2000 | WO2000040714A2 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | WO2000040705A2 Human desaturase gene and uses thereof |
| 07/13/2000 | WO2000040699A2 Astrocytes, their preparation and uses thereof |
| 07/13/2000 | WO2000040693A2 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 07/13/2000 | WO2000040614A2 Characterization of the soc/crac calcium channel protein family |
| 07/13/2000 | WO2000040605A2 Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids |
| 07/13/2000 | WO2000040597A1 Method and composition for angiogenesis inhibition |
| 07/13/2000 | WO2000040595A1 Antisense modulation of novel anti-apoptotic bcl-2-related proteins |
| 07/13/2000 | WO2000040592A1 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof |
| 07/13/2000 | WO2000040591A1 Protonated/acidified nucleic acids and methods of use |
| 07/13/2000 | WO2000040589A2 Novel derivatives from the class of oleandomycin |
| 07/13/2000 | WO2000040584A2 Process for preparing n6-substituted deaza-adenosine derivatives |
| 07/13/2000 | WO2000040583A2 Imidazo[4,5-c]-pyridine-4-on-derivatives |
| 07/13/2000 | WO2000040580A1 3,4-dihydro-2h-benzo[1,4]oxazinyl-methyl[3-(1h-indol-3-yl)-alkyl]-amines |
| 07/13/2000 | WO2000040579A1 New 1,4-disubstituted cyclohexane derivatives for the treatment of depression |
| 07/13/2000 | WO2000040578A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 07/13/2000 | WO2000040576A2 Thiopyran compounds as inhibitors of mmp |
| 07/13/2000 | WO2000040574A1 1,4-diazacycloheptane compounds, process for their preparation, and their use as medicaments |
| 07/13/2000 | WO2000040573A1 Method for high yield extraction of paclitaxel from paclitaxel-containing material |
| 07/13/2000 | WO2000040572A1 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands |
| 07/13/2000 | WO2000040571A1 Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity) |
| 07/13/2000 | WO2000040569A1 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 07/13/2000 | WO2000040565A1 Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors |
| 07/13/2000 | WO2000040564A1 N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase |
| 07/13/2000 | WO2000040563A1 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
| 07/13/2000 | WO2000040561A1 Quinolinecarboxamides as antiviral agents |
| 07/13/2000 | WO2000040560A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |